Obstetrics & Gynecology · Medical Literature
The BioSynIRS trial: biologic versus synthetic mesh for multicompartment pelvic floor reconstruction.
Abstract
Selected patients with obstructed defecation syndrome (ODS) and concomitant pelvic organ prolapse (POP) may require laparoscopic resection rectopexy (L-RRP) with laparoscopic sacrocolpopexy (L-SCP). This trial compared the safety and efficacy of biologic versus synthetic mesh (BM or SM) in L-SCP. In this single-center randomized pilot trial, 30 women with severe ODS underwent combined L-RRP and L-SCP using either a BM or SM. The primary endpoint was the severe adverse event rate. Secondary endpoints included functional and anatomical outcomes related to ODS and POP. Follow-up was complete at 12 months for all patients. The 30 patients (15 per group) had similar baseline characteristics, comparable frequency of additional surgical procedures, longer operative time in the SM group, lower pain in the BM group, similar length of hospital stay, comparable adverse event rates, and no mesh-related complications. Severe adverse events were reported by two patients (13%) in the BM group versus five (33%) in the SM group. Functional outcomes and POP-Q scores significantly improved in both groups (p < 0.01), urinary incontinence was unchanged, and there were three cases of ODS recurrence at 12 months. The main limitation of this study is its pilot design with a limited sample size and short follow-up, precluding definitive conclusions regarding long-term durability and rare adverse events. No significant differences in safety were detected between biologic and synthetic mesh; functional and anatomical outcomes improved similarly. Given the pilot design and limited sample size, these findings support the feasibility, but not equivalence or non-inferiority, of the biologic mesh. Adequately powered trials are required to confirm these findings and to evaluate the long-term durability of the biologic mesh. Trial registration at ClinicalTrials.gov (NCT06245577) and at the German Clinical Trials Register (DRKS00033079).
Clinical relevance
In women with severe obstructed defecation syndrome and concomitant pelvic organ prolapse undergoing combined laparoscopic resection rectopexy and laparoscopic sacrocolpopexy, does biologic mesh compare favorably to synthetic mesh with respect to severe adverse event rate and functional outcomes at 12 months? __SNAPSHOT__ {"studyDesign":"Single-center randomized pilot trial","setting":"Single center; country not reported in abstract","sampleSize":"n=30 (biologic mesh: n=15; synthetic mesh: n=15)","population":"Women with severe obstructed defecation syndrome (ODS) and concomitant pelvic organ prolapse (POP) requiring combined laparoscopic resection rectopexy (L-RRP) and laparoscopic sacrocolpopexy (L-SCP); baseline characteristics reported as similar between groups","intervention":"Biologic mesh (BM) used in laparoscopic sacrocolpopexy as part of combined L-RRP + L-SCP","comparator":"Synthetic mesh (SM) used in laparoscopic sacrocolpopexy as part of combined L-RRP + L-SCP","primaryOutcome":"Severe adverse event rate at 12 months","followUp":"12 months (complete for all 30 patients)","fundingSource":"Not reported"}
Key findings
The primary endpoint — severe adverse event rate — was 13% (2/15) in the biologic mesh group versus 33% (5/15) in the synthetic mesh group. The absolute risk difference favors biologic mesh by 20 percentage points (calculated), and the number needed to harm with synthetic mesh is approximately 5 (calculated); however, confidence intervals and p-values for this comparison are not reported in the abstract, and the trial was explicitly a pilot study not powered to detect a statistically significant difference in this endpoint. No mesh-related complications were observed in either group. Operative time was longer in the synthetic mesh group (specific values not reported). Postoperative pain was lower in the biologic mesh group (quantitative values not reported). Length of hospital stay was comparable between groups. Functional outcomes (specific instruments not named in the abstract) and POP-Q scores improved significantly in both groups (p < 0.01 for each group), with no between-group comparison reported. Urinary incontinence rates were unchanged in both groups. Three cases of an unspecified outcome were reported, but the abstract as provided is truncated and the nature of these events is not reported.
Practice implications
This pilot RCT provides preliminary, hypothesis-generating data suggesting that biologic mesh may be associated with a numerically lower severe adverse event rate compared to synthetic mesh in the specific combined L-RRP + L-SCP procedure for women with severe ODS and POP. Both mesh types produced statistically significant anatomical and functional improvement at 12 months, and neither was associated with mesh-specific complications during the observation period. However, several critical limitations preclude any change in clinical practice: the trial was explicitly designed as a pilot study (n=30) and was not statistically powered to detect differences in adverse event rates or clinical outcomes; no between-group inferential statistics for the primary or functional endpoints are reported; the 12-month follow-up is insufficient to capture long-term mesh complications, particularly the degradation-related recurrence risk theoretically associated with biologic mesh; and the abstract is truncated, leaving the nature of the three additional cases unreported. The findings do not apply broadly — they are limited to women with severe ODS requiring the specific combined interdisciplinary procedure, and patients are not generalizable to those undergoing sacrocolpopexy alone for POP. Current German guidelines do not recommend biologic mesh for sacrocolpopexy, and this study is insufficient to overturn that recommendation. Confirmation in an adequately powered trial with longer follow-up (minimum 3–5 years) is required before clinical practice should be reconsidered. NOTE: Only the abstract was available for review; full-text data including statistical analyses, adverse event details, and patient-reported outcome instrument results were not accessible. __LIMITATIONS__ Pilot trial explicitly underpowered (n=30, 15 per arm); not designed or powered to detect statistically significant differences in the primary endpoint or any secondary outcome.,No between-group inferential statistics (p-values, confidence intervals, or effect sizes) are reported for the primary endpoint or functional outcomes.,Follow-up limited to 12 months — insufficient to detect late mesh-related complications (erosion, migration for synthetic mesh) or recurrence from biologic mesh degradation (which occurs over 12–18 months).,Single-center design limits generalizability; institutional expertise in combined L-RRP + L-SCP is highly specialized and may not be reproducible elsewhere.,Abstract is truncated; three cases of an unreported event type are mentioned but not described, representing an incomplete safety profile.,Functional outcome instruments and POP-Q stage distributions are not specified in the abstract; between-group functional comparisons are not reported.,Funding source is not disclosed; potential conflicts of interest cannot be assessed.,Selection bias inherent to a highly selected surgical population (severe ODS requiring combined interdisciplinary procedure); results may not generalize to women undergoing L-SCP alone.,Operative time difference favoring biologic mesh not quantified; clinical relevance cannot be assessed.,Urinary incontinence was unchanged in both groups — potential safety signal not explored further in available abstract. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This small pilot RCT (n=30) found a numerically lower severe adverse event rate with biologic versus synthetic mesh (13% vs. 33%) in combined laparoscopic resection rectopexy plus sacrocolpopexy, with significant anatomical and functional improvement in both groups at 12 months and no mesh-related complications in either arm. The study is critically underpowered, lacks between-group inferential statistics, has insufficient follow-up to assess long-term mesh behavior, and is based on a truncated abstract — findings are hypothesis-generating only. Practice should not change on the basis of this trial; an adequately powered multicenter RCT with a minimum of 3–5 years of follow-up is required before biologic mesh can be recommended over synthetic mesh for laparoscopic sacrocolpopexy.